Novartis Wins Appeal for First Biosimilar to Go On Sale in US

Maier_03Novartis International has won FDA approval for a biosimilar of an existing drug. The drug, a copy of Amgen’s Neupogen, is designed to boost white blood cell counts in certain patients. An abbreviated FDA approval pathway for biologic medical products that share most of their properties with an existing, approved biologic product was created by the Biologics Price Competition and Innovation Act, passed as part of President Obama’s healthcare reform package. This, however, marks the first time the FDA has actually approved a biosimilar drug, though a number of others are pending approval.

While this new pathway is expected to save the U.S. healthcare system billions per year, many drug companies and other critics charge that it weakens patent protections and harms research and development by allowing competitors to bring their drugs to market earlier.

source: Maier & Maier, PLLC

345 South Patrick Street
Alexandria, VA 22314
www.maierandmaier.com

    • March 2024
      Mon Tue Wed Thu Fri Sat Sun
      « Jan    
       123
      45678910
      11121314151617
      18192021222324
      25262728293031
  • IP4all Weekly Bulletin

    You can subscribe to the weekly IP4ALL Bulletin.

  • IP Consulting Ltd. - Intellectual Property Consulting Agency
  • Landmark-TP
  • Ivan Georgiev - Rembrand
  • Global IP Attorneys - The world's leading address guide for patent,  trademark, copyright, intellectual property and IP attorneys. In just a few steps you can find your agency for registration and protection of your intellectual property, patent, design, copyright or trademark.
  • The Professional Sector Network is a referral and networking group that caters exclusively to leading firms with a history of excellence in the business, advisory and investment sectors.
  • Online source of information for the events and developments in the field of intellectual property worldwide
  • Jobs in USA
  • Become our partners
  • IP Basis®

  • IP Guide®